Natera (NASDAQ:NTRA) CFO Michael Burkes Brophy Sells 23,948 Shares of Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 23,948 shares of the firm’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $234.74, for a total value of $5,621,553.52. Following the completion of the sale, the chief financial officer owned 99,776 shares in the company, valued at $23,421,418.24. The trade was a 19.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Michael Burkes Brophy also recently made the following trade(s):

• On Wednesday, January 21st, Michael Burkes Brophy sold 37,175 shares of Natera stock. The stock was sold at an average price of $242.54, for a total transaction of $9,016,424.50.
• On Wednesday, October 29th, Michael Burkes Brophy sold 1,867 shares of Natera stock. The shares were sold at an average price of $190.64, for a total transaction of $355,924.88.
• On Tuesday, October 28th, Michael Burkes Brophy sold 2,415 shares of Natera stock. The stock was sold at an average price of $191.16, for a total transaction of $461,651.40.
• On Monday, October 27th, Michael Burkes Brophy sold 781 shares of Natera stock. The shares were sold at an average price of $192.32, for a total transaction of $150,201.92.
• On Friday, October 24th, Michael Burkes Brophy sold 755 shares of Natera stock. The shares were sold at an average price of $196.77, for a total value of $148,561.35.

Natera Trading Up 0.1%

Shares of NASDAQ NTRA opened at $242.91 on Friday. Natera, Inc. has a 12-month low of $125.38 and a 12-month high of $256.36. The company has a market cap of $33.60 billion, a PE ratio of -106.07 and a beta of 1.62. The stock has a 50 day simple moving average of $233.44 and a 200-day simple moving average of $190.60.

Natera (NASDAQ:NTRA) last posted its earnings results on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.25). Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. The business had revenue of $592.18 million during the quarter, compared to analyst estimates of $514.55 million. During the same quarter in the prior year, the business earned ($0.26) earnings per share. The firm’s revenue was up 34.7% compared to the same quarter last year. Sell-side analysts forecast that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

More Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera published peer‑reviewed clinical validation of its Latitude™ tissue‑free MRD test for colorectal cancer in npj Precision Oncology — a data milestone that strengthens clinical credibility and could accelerate adoption of a high‑value diagnostic product. Natera Publishes Clinical Validation of Latitude™ Tissue-Free MRD Test in Colorectal Cancer
• Negative Sentiment: CEO Steven Leonard Chapman sold a material block of shares (71,932 shares on Jan 20 and additional smaller sales on Jan 21), reducing his stake by roughly 24.9% from prior levels — a large, high‑profile insider sale that may be viewed negatively by the market. CEO Form 4
• Negative Sentiment: CFO Michael Burkes Brophy disclosed substantial sales (23,948 and 37,175 shares across Jan 20–21), cutting his ownership materially (~36.7% decrease on later filing) — another large insider liquidation that can weigh on near‑term sentiment. CFO Form 4
• Negative Sentiment: Other insiders (John Fesko and Solomon Moshkevich) also sold shares on Jan 20–21 (multiple transactions totaling tens of thousands of shares combined), modestly reducing their stakes. These coordinated/clustered sales increase perceived supply risk. Insider Form 4 example

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in NTRA. JPMorgan Chase & Co. lifted its position in shares of Natera by 44.3% during the 2nd quarter. JPMorgan Chase & Co. now owns 10,625,785 shares of the medical research company’s stock valued at $1,795,125,000 after acquiring an additional 3,263,822 shares during the last quarter. Norges Bank acquired a new position in shares of Natera in the 2nd quarter worth $277,749,000. Franklin Resources Inc. raised its position in shares of Natera by 37.5% during the third quarter. Franklin Resources Inc. now owns 2,665,013 shares of the medical research company’s stock worth $428,987,000 after purchasing an additional 727,366 shares during the period. AQR Capital Management LLC lifted its holdings in shares of Natera by 39.0% during the third quarter. AQR Capital Management LLC now owns 2,400,065 shares of the medical research company’s stock valued at $386,338,000 after purchasing an additional 673,315 shares during the last quarter. Finally, Millennium Management LLC boosted its position in shares of Natera by 215.7% in the 3rd quarter. Millennium Management LLC now owns 527,942 shares of the medical research company’s stock valued at $84,983,000 after purchasing an additional 360,733 shares during the period. Institutional investors and hedge funds own 99.90% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on NTRA shares. Barclays raised their target price on shares of Natera from $230.00 to $270.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Guggenheim raised their price objective on shares of Natera from $230.00 to $270.00 and gave the company a “buy” rating in a research note on Monday, January 5th. TD Cowen restated a “buy” rating on shares of Natera in a research report on Wednesday, January 7th. BNP Paribas Exane raised Natera to a “hold” rating and set a $172.00 price target for the company in a research note on Monday, October 27th. Finally, Citigroup started coverage on Natera in a research note on Wednesday, January 7th. They issued a “buy” rating and a $300.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $245.50.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.